Is ADMA Biologics, Inc. (ADMA) a Buy, Sell, or Hold?
ADMA Biologics, Inc.
NASDAQ:ADMA
$8.87 USD
-$0.1 (-1.11%)
- Volume
- 2.7M
- Average Volume
- 5.01M
- Market Capitalization
- $2.06B
- P/E Ratio
- 12.86
- Dividend Yield
- 0.00%
- Price Target
- $21.00
- Year High
- $20.46
- Year Low
- $7.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.95
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Adam S. Grossman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADMA |
| CUSIP | 000899104 |
| CIK | 0001368514 |
| Web | https://www.admabiologics.com |
| Phone | 201 478 5552 |
| Currency | USD |
| Employees | 647 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.52 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.95 |
| Quick Ratio | 3.93 |
| Cash Ratio | 1.88 |
Sales & Book Value
| Annual Sales | $510.17M |
| Price / Sales | 4.03 |
| Cash Flow | 0.46 |
| Price / Cash Flow | 19.05 |
| Price / Book | 5.36 |
Price Target and Rating
| Average Stock Price Forecast | $21.00 |
| High Stock Price Forecast | $24.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -57.76% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.6 |
| Trailing P/E Ratio | 12.86 |
| PEG Ratio | -0.62 |
| P/E Growth | -0.62 |
| Net Income | $146.93M |
| Net Margin | 32.43% |
| Pretax Margin | 40.47% |
| Return on Equity | 38.97% |
| Return on Assets | 24.86% |
Financials Score
| AltmanZ Score | 6.86 |
| Piotroski Score | 6.00 |
| Working Capital | 437.63M |
| Total Assets | 665.18M |
| Ebit | 213.57M |
| Market Cap | 2.06B |
| Total Liabilities | 274.86M |
Poll Results
About ADMA Biologics, Inc. (NASDAQ:ADMA) Stock
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes ... immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
2026-07-14 22:41:00
NEW YORK and NEW ORLEANS, July 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.
2026-07-14 17:30:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
2026-07-14 12:37:00
New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2026-07-14 10:07:00
NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
2026-07-14 10:05:00
Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own headquarters.
2026-07-14 07:45:00
SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.
2026-07-14 06:21:00
A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, July 14, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
2026-07-13 19:21:00
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Frequently Asked Questions
-
What is the current ADMA Biologics, Inc. (ADMA) stock price?
-
ADMA Biologics, Inc.(NASDAQ:ADMA) stock price is $8.87 in the last trading session. During the trading session, ADMA stock reached the peak price of $20.458 while $7.21 was the lowest point it dropped to. The percentage change in ADMA stock occurred in the recent session was --1.11% while the dollar amount for the price change in ADMA stock was -$-0.1.
-
ADMA's industry and sector of operation?
-
The NASDAQ listed ADMA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADMA?
-
Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance
Skyler Bloom | Senior Director of Business Development & Corporate Strategy
Terence Kohler | Chief Financial Officer & Treasurer
Jerrold Grossman | Co-Founder & Vice Chairman of the Board
Michael Goldstein | General Counsel -
How many employees does ADMA have?
-
Number of ADMA employees currently stands at 647. ADMA operates from 465 State Route 17, Ramsey, NJ 07446, US.
-
Link for ADMA official website?
-
Official Website of ADMA is: https://www.admabiologics.com
-
How do I contact ADMA?
-
ADMA could be contacted at phone #201 478 5552 and can also be accessed through its website. ADMA operates from 465 State Route 17, Ramsey, NJ 07446, US.
-
How many shares of ADMA are traded daily?
-
The average number of ADMA shares traded daily for last 3 months was 5.01M.
-
What is the market cap of ADMA currently?
-
The market value of ADMA currently stands at $2.06B with its latest stock price at $8.87